
Aficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.
This FDA News Month in Review provides a round-up of regulatory decisions from November 2025.
Welcome back to our recap of this month's news and updates from the






